Marshall Wace LLP Boosts Stock Position in AtriCure, Inc. (NASDAQ:ATRC)

Marshall Wace LLP boosted its holdings in AtriCure, Inc. (NASDAQ:ATRC - Free Report) by 37.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 619,166 shares of the medical device company's stock after buying an additional 167,476 shares during the quarter. Marshall Wace LLP owned approximately 1.27% of AtriCure worth $18,922,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in the business. Heck Capital Advisors LLC bought a new stake in shares of AtriCure in the 4th quarter valued at $60,000. Venturi Wealth Management LLC boosted its position in shares of AtriCure by 1,337.6% during the 4th quarter. Venturi Wealth Management LLC now owns 2,257 shares of the medical device company's stock valued at $69,000 after purchasing an additional 2,100 shares in the last quarter. KBC Group NV boosted its position in shares of AtriCure by 65.3% during the 4th quarter. KBC Group NV now owns 2,360 shares of the medical device company's stock valued at $72,000 after purchasing an additional 932 shares in the last quarter. R Squared Ltd acquired a new stake in AtriCure during the fourth quarter worth approximately $89,000. Finally, AlphaQuest LLC increased its holdings in AtriCure by 855.1% in the fourth quarter. AlphaQuest LLC now owns 5,062 shares of the medical device company's stock worth $155,000 after purchasing an additional 4,532 shares in the last quarter. 99.11% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several analysts have recently commented on ATRC shares. Oppenheimer raised their price objective on shares of AtriCure from $36.00 to $45.00 and gave the stock an "outperform" rating in a research report on Thursday, February 13th. Stifel Nicolaus increased their price objective on shares of AtriCure from $36.00 to $48.00 and gave the stock a "buy" rating in a research report on Thursday, February 13th. BTIG Research reiterated a "buy" rating on shares of AtriCure in a report on Thursday, March 27th. Canaccord Genuity Group decreased their price objective on AtriCure from $66.00 to $52.00 and set a "buy" rating for the company in a report on Friday, March 28th. Finally, JPMorgan Chase & Co. lowered their target price on AtriCure from $51.00 to $46.00 and set an "overweight" rating on the stock in a research report on Thursday, March 27th. One equities research analyst has rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat, AtriCure has a consensus rating of "Moderate Buy" and an average price target of $49.44.

AtriCure Price Performance

Shares of AtriCure stock traded up $1.26 on Thursday, reaching $33.75. The stock had a trading volume of 526,034 shares, compared to its average volume of 653,221. The business's 50 day moving average is $34.56 and its two-hundred day moving average is $34.46. The company has a market cap of $1.65 billion, a P/E ratio of -35.53 and a beta of 1.65. AtriCure, Inc. has a 1 year low of $18.94 and a 1 year high of $43.11. The company has a current ratio of 3.65, a quick ratio of 2.62 and a debt-to-equity ratio of 0.13.

Insider Buying and Selling at AtriCure

In other AtriCure news, Director Karen Prange sold 6,100 shares of AtriCure stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $38.12, for a total transaction of $232,532.00. Following the transaction, the director now directly owns 17,828 shares of the company's stock, valued at approximately $679,603.36. This trade represents a 25.49 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 3.20% of the stock is currently owned by company insiders.

AtriCure Company Profile

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.